Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 19/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 19/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 11/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.49 |
| ▸ | CDC7 | O00311 | 10/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634511 | 1.00 | PIM1 (0.49) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL24388438 | 0.88 | PIM1 (0.38) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL4738033 | 0.85 | PIM1 (0.50) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL2494411 | 0.84 | KMT2A (0.66) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL30117918 | 0.84 | KMT2A (0.66) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL30365029 | 0.80 | CSNK2B (0.49) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL20029917 | 0.80 | CSNK2B (0.49) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL20024750 | 0.80 | CSNK2B (0.49) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL29565166 | 0.78 | PIM1 (0.54) | PIM1CSNK2BCSNK2A2PIM3PIM2 | |
| SCHEMBL24388208 | 0.78 | PIM1 (0.54) | PIM1CSNK2BCSNK2A2PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237506-B1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2024-07-17 | — | — | EP | disclosed |
| US-12030890-B2 | Compounds with diazadibenzofurane or diazadibenzothiophene structures | MERCK PATENT GMBH (DE) | 2024-07-09 | — | — | US | disclosed |
| US-12030890-B2 | Compounds with diazadibenzofurane or diazadibenzothiophene structures | MERCK PATENT GMBH (DE) | 2024-07-09 | — | — | US | disclosed |
| US-20230389344-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230389344-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| US-11530224-B2 | Compounds with diazadibenzofurane or diazadibenzothiophene structures | MERCK PATENT GMBH (DE) | 2022-12-20 | — | — | US | disclosed |
| EP-3519415-B1 | CARBAZOLES WITH DIAZADIBENZOFURANE OR DIAZADIBENZOTHIOPHENE STRUCTURES | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022090108-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| EP-3519417-B1 | COMPOUNDS WITH DIAZADIBENZOFURANE OR DIAZADIBENZOTHIOPHENE STRUCTURES | MERCK PATENT GMBH (DE) | 2021-09-08 | — | — | EP | disclosed |
| WO-2018060307-A1 | COMPOUNDS WITH DIAZADIBENZOFURANE OR DIAZADIBENZOTHIOPHENE STRUCTURES | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018060218-A1 | CARBAZOLES WITH DIAZADIBENZOFURANE OR DIAZADIBENZOTHIOPHENE STRUCTURES | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | WO | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | PIM1 1977/4885CSNK2B 350/4885CSNK2A2 906/4885 |
| US-12030890-B2 | Compounds with diazadibenzofurane or diazadibenzothiophene structures | DDT, ESD, DBF4 | PIM1 344/4885CSNK2B 4537/4885CSNK2A2 4573/4885 |
| US-11530224-B2 | Compounds with diazadibenzofurane or diazadibenzothiophene structures | DDT, ESD, DBF4 | PIM1 344/4885CSNK2B 4537/4885CSNK2A2 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.